NCT06032845View on ClinicalTrials.gov

Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11)

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 13, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
Solid Tumor, Adult
Interventions
DRUG

Tislelizumab

a PD-1 immune check inhibitor

DRUG

Lenvatinib

Lenvatinib capsules

PROCEDURE

Cryoablation

Cryoablation is performed under US or CT guidance per Investigator decision.

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER